Opus Genetics (IRD) Interest Expenses (2011 - 2026)

Opus Genetics (IRD) posted quarterly Interest Expenses of $100000.0 for Q1 2026, little changed quarter-over-quarter from $100000.0 in Q3 2025.

Opus Genetics (IRD) Interest Expenses (2011 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Interest Expenses for 14 consecutive years, with $100000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Interest Expenses changed N/A year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $200000.0 (changed N/A YoY), while the FY2025 annual figure was $40.0 million, changed N/A from the prior year.
Interest Expenses held at $100000.0 in Q1 2026 per IRD's latest filing, from $100000.0 in the prior quarter.
Across five years, Interest Expenses topped out at $100000.0 in Q3 2025 and bottomed at $4000.0 in Q2 2022.
Historically, Interest Expenses has averaged $52250.0 across 3 years, with a median of $52500.0 in 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	439.40 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	52.50 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.70 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	39.74 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	335,572.77
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	218.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	82.05 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	20.27 Mn
10	Opus Genetics	298.36 Mn	209.55 Mn	-	100,000.00

Download Data